Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

One-Year Follow-up on Liraglutide Treatment for Prediabetes and Overweight/Obesity in Clozapine- or Olanzapine-Treated Patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Reducing the rate of psychiatric Re-ADMISsions in Bipolar Disorder using smartphones The RADMIS trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Familial risk and heritability of depression by age at first diagnosis in Danish twins

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hippocampal Volume and Memory Impairment after Electroconvulsive Therapy in Patients with Depression

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. High suicide rates during psychiatric inpatient stay and shortly after discharge

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Oral contraceptives and the serotonin 4 receptor: a molecular brain imaging study in healthy women

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Treatment with most antipsychotics is associated with an increased risk of weight gain and metabolic disturbances. In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. The aim of this study was to investigate whether the beneficial effects of the 16-week intervention were sustained beyond the intervention period.

METHOD: One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide and lipids comparing one-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.

RESULTS: From end of treatment to the one-year follow-up, body weight had increased in the liraglutide-treated group. However, compared to baseline levels, the placebo-subtracted body weight loss remained significantly reduced (-3.8 kg, 95% CI: -7.3 to -0.2, P = 0.04). Fasting glucose, glycated hemoglobin, C-peptide and lipids had each returned to baseline levels one year after stopping liraglutide.

CONCLUSION: The body weight reduction during 16 weeks of liraglutide treatment was partially sustained one year after the intervention was completed. However, the improvements in other metabolic parameters returned to baseline levels. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalActa Psychiatrica Scandinavica
Volume139
Issue number1
Pages (from-to)26-36
Number of pages11
ISSN0001-690X
DOIs
Publication statusPublished - Jan 2019

Bibliographical note

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

    Research areas

  • clozapine, GLP-1, liraglutide, olanzapine, overweight, prediabetes, schizophrenia

ID: 55633064